Medical Devices: 70%
Hospital Supplies: 20%
Pharmaceutical Products: 10%

TOP 3 Markets:
India: 40%
Europe: 30%
USA: 20%

Poly Medicure Limited generates the majority of its revenue from the manufacturing and distribution of medical devices, which account for approximately 70% of total revenue. Another significant portion is attributed to hospital supplies, while pharmaceutical products make up a smaller portion of the revenues.

Geographically, India is the largest market for the company, followed by Europe and the USA. These markets are crucial for the growth and expansion of Poly Medicure, as they exhibit high demand for medical devices and products.

Production sites of Poly Medicure Limited:

Poly Medicure Limited operates several production facilities in India. The main locations are:

• Faridabad, Haryana
• Jaipur, Rajasthan
• Haridwar, Uttarakhand

In addition, the company also has production capacities in China. These international sites support the global market presence and help efficiently meet demand in various regions.

Revenue Growth: 18.5% (2025) Profit Growth: 14.2% (2025)

Poly Medicure Limited pursues a growth strategy that heavily focuses on innovation and expansion into new markets. The company continuously invests in research and development to expand its product portfolio and introduce new, innovative medical devices to the market.

Another key focus is on geographical expansion, particularly into emerging markets in Asia and Africa, where the demand for high-quality medical devices is increasing. Poly Medicure has also established strategic partnerships and joint ventures to strengthen its market presence and explore new distribution channels.

Additionally, the company is optimizing its production processes to increase efficiency and reduce costs, with the long-term goal of improving profit margins. These measures are intended to ensure that Poly Medicure can further enhance its position as a leading provider in the medical technology industry.

Main raw materials: Plastic resins, medical plastics, silicones

Main importing countries: China, Germany, USA

Poly Medicure Limited mainly imports plastic resins and medical plastics needed for the production of their medical devices and consumables. These materials are crucial for the manufacturing of high-quality medical products.

China is one of the largest suppliers of plastic resins due to its significant production capacity in this field. Germany and the USA are also important partners, especially for specialized medical plastics and silicones used in advanced medical applications.

These import strategies enable Poly Medicure to access high-quality materials necessary for complying with international quality standards.

Market Share: Estimated 10-15% in the Indian market for medical devices (2025)

Research and Development (R&D) Expenses: 5% of revenue (2025)

Export Share: Over 60% of total revenue (2025)

Poly Medicure Limited has established itself as one of the leading providers in the field of medical disposable products. The company's competitive advantage lies in its strong presence in both domestic and international markets.

The company continuously invests in research and development, enabling it to develop innovative products and differentiate itself from the competition. Another important factor is the high export share, which makes the company less vulnerable to local market fluctuations.

In addition, Poly Medicure benefits from a wide range of products and an efficient production infrastructure, allowing the company to produce cost-effectively while maintaining high quality standards. Together, these factors give Poly Medicure a solid competitive edge in the industry.

Institutional Investor Share: Estimated 30-40% (2026)

Insider Buys/Sells: No significant transactions in the last year (2026)

The institutional investor share in Poly Medicure Limited typically ranges between 30 and 40 percent. These investors usually include pension funds, investment funds, and other large financial institutions aiming for long-term investments.

In 2026, there were no significant insider transactions indicating a change in management or major shareholders' confidence in the company's future development. This suggests that the management and insiders are satisfied with the current corporate strategy and see no need to make significant changes to their positions.

Market share of Poly Medicure Limited: Estimated 5-7% (2026)

Top competitors and their market share:

1. B. Braun Melsungen AG: 15%
2. Baxter International Inc.: 12%
3. Fresenius Medical Care AG & Co. KGaA: 10%
4. Terumo Corporation: 8%
5. Smiths Medical: 6%
6. Poly Medicure Limited: 5-7%
7. Nipro Corporation: 4%
8. Medtronic plc: 3%
9. Becton, Dickinson and Company: 2%
10. Hollister Incorporated: 1%

Moat of Poly Medicure Limited:

Poly Medicure Limited has made a name for itself in recent years through its cost-efficient production and a wide product portfolio in the field of medical disposable items. The company's moat is mainly based on its strong presence in emerging markets, where it benefits from local production facilities and a well-established distribution network.

Compared to larger competitors like B. Braun or Baxter, which have extensive research and development resources as well as global brand recognition, Poly Medicure's moat is less pronounced. These larger companies often have stronger innovation capabilities and can better leverage economies of scale due to their size.

However, Poly Medicure has a certain advantage in price-sensitive markets due to its focus on cost-effective solutions and quick adaptability to market needs. This can be seen as a specific, albeit limited, moat.

Revenue Growth: 18% (2025) Profit Growth: 15% (2025) Return on Equity: 20% (2025)

Poly Medicure Limited recorded strong revenue growth of 18% in 2025, attributed to expansion into new markets and the introduction of innovative medical products. The company also achieved a profit growth of 15%, indicating efficient cost control and improved production processes.

The 20% return on equity demonstrates the company's ability to effectively utilize its investments to enhance shareholder value. This metric is an indicator of profitability and the company's ability to generate profits from its equity.

In summary, Poly Medicure Limited's financial performance suggests a solid growth strategy and a strong market position. These factors could make the stock an attractive investment, especially for investors focusing on long-term growth.

Dividend yield: 0.8% (2025) Dividend history: Continuous payout over the last 5 years

Poly Medicure Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The dividend yield was 0.8% in 2025, which is rather moderate compared to other companies in the industry.

The company has a solid financial foundation and demonstrates a continuous growth strategy, increasing the likelihood that the dividend policy will continue in the future. However, analysts note that the company reinvests a larger portion of its profits in growth initiatives, which could affect the dividend yield.